Neuro-Ophthalmic Manifestations of Glioblastoma Multiforme

Glioblastoma multiforme (GBM) is an aggressive brain cancer that grows quickly and spreads into nearby brain tissue. It is the most common malignant brain tumor in adults. As the tumor grows, it raises pressure inside the skull, irritates brain tissue, and can damage the pathways that carry visual signals from the eyes to the brain. When GBM affects these visual pathways, people develop neuro-ophthalmic problems. These are eye and vision problems that come from the brain or the nerves behind the eye, not from the eye surface itself. NCBIPMCCancer.gov

The visual pathway runs from the optic nerves to the optic chiasm (where fibers cross), then to the optic tracts, lateral geniculate nucleus, optic radiations through the temporal and parietal lobes, and finally to the occipital visual cortex. A tumor can injure any of these stops. Damage at different places causes different patterns of vision loss. For example, lesions of the temporal “Meyer’s loop” often cause an upper-quadrant blind area, while occipital lesions often cause a homonymous hemianopia. These patterns help doctors localize where the tumor is sitting. Radiopaedia+1NCBI

GBM can also affect the eye movement nerves (cranial nerves III, IV, VI), the pupil pathways, and centers that control eye positions and eyelids. Pressure in the skull can also swell the optic nerves, causing papilledema. These mechanisms explain most neuro-ophthalmic problems in GBM. Chinese Clinical OncologyEyeWiki

Sometimes GBM grows directly in the optic pathway itself (for example, the optic nerve, chiasm, or tract), which can produce very specific eye findings such as rapid loss of vision, loss of color vision, and a relative afferent pupillary defect (RAPD). Visual field defects can be the first or the earliest sign of tumor growth or progression. EyeWikiPMCDove Medical Press

---

Types of neuro-ophthalmic manifestations in GBM

Below are the common types, grouped by where the tumor or swelling acts. Each type includes a plain-English description of what the patient may notice and what the examiner may find.

1. Optic nerve dysfunction (compressive or infiltrative). Vision in one eye drops. Colors, especially red, look washed out. A pupil test shows RAPD. The optic disc may look swollen early and pale later. EyeWiki

2. Chiasmal syndrome. Both eyes lose the outer (temporal) halves of vision (bitemporal hemianopia). This happens when the tumor or swelling presses the chiasm from below or behind. Pituitary-area or suprasellar extension can do this. (General background on localization.) Radiopaedia

3. Optic tract syndrome. Both eyes lose the same side of the visual field (homonymous hemianopia). A special pupil finding may appear: a RAPD in the eye opposite the lesion. Over time, the optic discs can show a “bow-tie” pattern of pallor. NCBIPMC

4. Lateral geniculate nucleus involvement. Patients can have sector-shaped blind areas. The pattern is often sharp and respects the vertical midline because the problem is in a relay station of the visual pathway. (General localization reference.) Radiopaedia

5. Temporal lobe (Meyer’s loop) involvement. People lose the upper-outer quadrant on the side opposite the lesion (“pie-in-the-sky”). Reading lines at the top of a page becomes hard. Face recognition may feel normal, but parts of the visual world are missing. NCBI

6. Parietal lobe optic radiations involvement. People lose the lower-outer quadrant on the opposite side (“pie-on-the-floor”). They may trip over low objects or miss steps. Radiopaedia

7. Occipital cortex involvement. People develop a homonymous hemianopia that is often very “clean” and respects the vertical line. Visual acuity and eye structures can look normal. There may be “macular sparing,” so central vision remains usable. Radiopaedia

8. Raised intracranial pressure with papilledema. Both optic nerves swell. Vision may blur transiently, especially when bending over or standing up (transient visual obscurations). Headache is common. Chronic swelling can lead to optic atrophy and permanent loss. EyeWikiAmerican Academy of Ophthalmology

9. Cranial nerve VI palsy (abducens). People see horizontal double vision, especially when looking far to the side. This nerve is easily stretched when pressure in the skull is high. Chinese Clinical Oncology

10. Cranial nerve III or IV palsy (cavernous sinus or skull-base spread). The eyelid may droop, the pupil may be big and unreactive (CN III), or vertical double vision may appear (CN IV). Pain around the eye can occur if the cavernous sinus is involved. AJR Online

11. Dorsal midbrain (Parinaud) syndrome. Upgaze is limited, near vision may trigger jerky eye movements (convergence-retraction nystagmus), and pupils may react poorly to light but better to near (light-near dissociation). Pineal-region mass or midbrain compression can cause this. EyeWikiNCBI

12. Nystagmus and gaze palsies. The eyes may drift or jerk when trying to hold gaze, depending on where the tumor irritates gaze centers or tracts. (General neuro-ophthalmic tumor review.) Chinese Clinical Oncology

13. Visual neglect (non-dominant parietal lobe). The person ignores one side of space even with normal eye structures. They bump into things on the neglected side.

14. Higher visual processing problems (occipito-temporal association areas). People may have difficulty reading (alexia), recognizing faces (prosopagnosia), or seeing more than one object at a time (simultanagnosia), depending on lesion location.

15. Horner syndrome (oculosympathetic pathway). One pupil is smaller, the upper eyelid droops slightly, and sweating can be decreased on that side of the face. Tumor along the sympathetic chain or cavernous sinus can do this. EyeWikiNCBI

---

Causes

Each “cause” here is a mechanism by which GBM produces neuro-ophthalmic problems.

1. Direct optic nerve invasion by tumor cells reduces signal from that eye. EyeWiki

2. Compression of the optic chiasm causes bitemporal field loss. Radiopaedia

3. Involvement of the optic tract causes homonymous hemianopia with a possible contralateral RAPD. NCBI

4. Pressure on the lateral geniculate nucleus alters sector vision patterns. Radiopaedia

5. Temporal lobe edema or tumor along Meyer’s loop causes superior quadrantanopia. NCBI

6. Parietal lobe optic radiation injury causes inferior quadrantanopia. Radiopaedia

7. Occipital cortex destruction causes congruous homonymous hemianopia. Radiopaedia

8. Raised intracranial pressure causes papilledema and transient visual dimming. EyeWiki

9. Obstructive hydrocephalus from tumor blocks cerebrospinal fluid and raises pressure, worsening papilledema. EyeWiki

10. Stretch of cranial nerve VI from pressure causes horizontal double vision. Chinese Clinical Oncology

11. Cavernous sinus or skull-base spread injures III, IV, VI, and V1, producing diplopia, ptosis, or eye pain. AJR Online

12. Dorsal midbrain compression produces Parinaud syndrome with upgaze palsy and pupil anomalies. EyeWiki

13. Leptomeningeal spread to the optic nerve sheath or CSF pathways causes diffuse visual and ocular motor problems. (General tumor spread background.) PMC

14. Intratumoral hemorrhage suddenly worsens field loss or vision from acute mass effect. PMC

15. Tumor-related venous sinus thrombosis raises intracranial pressure and papilledema. (IIH/ICP imaging and papilledema references.) Practical NeurologyEyeWiki

16. Radiation-induced optic neuropathy after treatment damages the anterior visual pathway. (Differentiation of recurrence vs necrosis uses perfusion/spectroscopy.) PLOS

17. Postoperative visual pathway injury after resection leads to new field defects or diplopia. (General GBM management background.) PMC

18. Seizure-related transient visual loss when occipital cortex is irritable can mimic tumor progression. NCBI

19. Posterior cerebral artery ischemia around tumor produces new occipital field loss. (Localization background.) Radiopaedia

20. Treatment-related syndromes (for example, PRES with certain drugs) can cause temporary visual symptoms during care. (General oncology/GBM therapy background.) PMC

---

Symptoms

1. Blurred or dim vision in one eye or both eyes. It can be constant or come and go. Mayo ClinicNational Organization for Rare Disorders

2. Loss of side vision on one side (homonymous hemianopia) or loss of outer halves in both eyes (bitemporal hemianopia). People bump into door frames or miss cars coming from one side. Radiopaedia

3. Color looks faded (especially red) in one eye, a sign of optic nerve dysfunction. EyeWiki

4. Transient visual obscurations—brief graying out of vision, often with posture change, from papilledema. EyeWiki

5. Double vision (horizontal or vertical), worse when looking in a certain direction. AJR Online

6. Droopy eyelid or large pupil with poor light reaction, suggesting a third-nerve problem. AJR Online

7. Trouble looking up and light-near pupil changes (Parinaud syndrome). EyeWiki

8. Eye jerks (nystagmus) or gaze holding trouble, especially with midbrain or cerebellar connections affected. Chinese Clinical Oncology

9. Headache with nausea and vomiting, often worse in the morning, from raised pressure. Cancer.gov

10. Visual neglect—ignoring one side of space, seen on drawing or line bisection tasks.

11. Reading problems—losing place on a page or trouble reading lines due to field loss or higher-order visual issues.

12. Face recognition trouble when occipito-temporal areas are involved.

13. Photopsias or visual auras (flashes or zigzags), sometimes linked to occipital irritation or seizures. NCBI

14. Eye or brow pain when cavernous sinus or skull-base structures are irritated. AJR Online

15. Worsening visual field defects over time, which can be an early sign of tumor progression and should trigger urgent reassessment. PMCDove Medical Press

---

Diagnostic tests

A) Physical exam

1. Visual acuity (Snellen or ETDRS). Measures how clearly each eye sees. It is simple but crucial. A big drop points to optic nerve or macular problems.

2. Pupil exam with the swinging flashlight test. Checks for a relative afferent pupillary defect (RAPD), which signals unequal input from the two optic nerves or tracts. EyeWiki

3. Color vision testing (Ishihara plates). Looks for color loss, which is sensitive to optic nerve disease. Red color is often most affected. PMC

4. Confrontation visual fields. A quick screen for field loss at the bedside. It suggests where the lesion may be.

5. Dilated fundus examination. Looks directly at the optic nerve head for papilledema or optic atrophy. In raised pressure, the disc is swollen; later it can look pale. EyeWiki

B) Manual/office functional tests

6. Automated perimetry (Humphrey visual field). Precisely maps field loss and tracks change over time. It is the gold-standard functional test to document hemianopia or quadrantanopia. NCBI

7. Cover–uncover and alternate prism cover tests. Identify and measure eye misalignment from cranial nerve palsies or skew. This explains many diplopia complaints. EyeWiki+1

8. Amsler grid. A simple grid to check central field defects and metamorphopsia. It helps document macular or optic nerve–related central problems. NCBI

9. Red desaturation (red cap) test. A quick bedside comparison of color intensity between the two eyes that suggests optic nerve dysfunction. EyeWikiPMC

C) Laboratory & pathological tests

10. Histopathology (H&E) from biopsy or resection. Confirms GBM by showing features like microvascular proliferation and necrosis in an IDH-wildtype diffuse astrocytic tumor. PMC

11. Immunohistochemistry for IDH1 R132H and ATRX. Adult GBM is typically IDH-wildtype and often ATRX-retained on staining. This helps classification. PMC

12. Molecular markers for GBM (EGFR amplification, TERT promoter mutation, +7/−10). Detection by FISH/NGS or sequencing supports the WHO 2021 definition of glioblastoma, IDH-wildtype even when classic histology is borderline. PMCCollege of American Pathologists

13. MGMT promoter methylation testing. Helps predict response to temozolomide and overall prognosis; it is widely used in clinical decision-making. PMC+1

D) Electrodiagnostic tests

14. Visual evoked potentials (VEP). Measures electrical responses from the visual cortex after a pattern stimulus. It can support a diagnosis of anterior or chiasmal pathway dysfunction, and it helps in optic pathway gliomas. Interpretation must consider that many OPGs involve the chiasm. PMCIOVS

15. Electroencephalography (EEG). Helps if visual auras or spells suggest occipital seizures rather than pure tumor-related field loss.

16. Quantitative pupillography of the swinging flashlight test. Provides an objective RAPD curve when the bedside exam is equivocal. Penn Medicine

E) Imaging tests

17. MRI brain with and without contrast (plus orbits when needed). This is the key test. It shows the mass, its location along the visual pathway, its effect on nearby structures, and signs of raised pressure or hydrocephalus. PMC

18. Optical coherence tomography (OCT) of the optic nerve and macula. OCT measures the retinal nerve fiber layer (RNFL) and ganglion cell complex (GCC). It helps detect papilledema, track axonal loss, and separate true swelling from pseudopapilledema. It is a powerful, objective tool to monitor neuro-ophthalmic damage over time. PMC+1Nature

19. MR perfusion (relative cerebral blood volume, rCBV). Helps grade gliomas and can help distinguish recurrence from treatment necrosis when symptoms change and MRI is unclear. PMCLippincott Journals

20. MR spectroscopy. Looks at brain chemicals; GBM typically shows elevated choline and reduced N-acetylaspartate, supporting high-grade disease and helping with difficult differentials. PMCEPOS

Non-pharmacological treatments

(therapies & practical supports; each with description • purpose • how it helps)

1. Vision rehabilitation (low-vision clinic).
   Description: A structured program run by neuro-ophthalmology/low-vision specialists.
   Purpose: Teach you to use the vision you still have.
   How it helps: Training in scanning strategies, reading with field loss, and using aids can improve day-to-day function even if the damaged wiring doesn’t fully recover. Lippincott Journals

2. Visual scanning (compensatory saccade) training.
   Description: Guided practice to move your eyes/head to “search” the blind side.
   Purpose: Reduce bumping, missing words, and navigation errors.
   How it helps: Builds a habit of exploring the missing field to improve safety and reading. PMC

3. Prism lenses (e.g., Fresnel prisms).
   Description: Thin prisms stuck on glasses.
   Purpose: Shift images from the blind side into the seeing side or join double images.
   How it helps: Can expand the “usable” field in hemianopia and help some kinds of double vision. American Academy of Ophthalmology

4. Partial occlusion/patching for double vision.
   Description: A patch or translucent tape over one lens.
   Purpose: Stop the brain from getting two images.
   How it helps: Immediate relief of double vision while other treatments progress.

5. Contrast and font adjustments.
   Description: Bigger, bold fonts; high-contrast settings; dark mode; e-readers.
   Purpose: Make text and screens easier to see.
   How it helps: Compensates for reduced acuity or visual field defects.

6. Magnification tools.
   Description: Hand/stand magnifiers, electronic video magnifiers, phone/tablet zoom.
   Purpose: Easier reading, labels, prices.
   How it helps: Makes small details legible with less strain.

7. Text-to-speech and screen readers.
   Description: Software reads text aloud (phone and computer).
   Purpose: Access information without relying on fine vision.
   How it helps: Bypasses visual load to reduce fatigue.

8. Orientation & mobility training (O&M).
   Description: Specialist coaching for safe walking and navigation.
   Purpose: Reduce falls and collisions.
   How it helps: Teaches route planning, scanning, and cane techniques if needed.

9. Home safety modifications.
   Description: Bright, even lighting; mark steps/edges; remove trip hazards; grab bars.
   Purpose: Prevent falls and injuries.
   How it helps: Compensates for field loss and depth-perception problems.

10. Driving cessation or formal driving rehab assessment.
    Description: Honest talk and professional on-road evaluation.
    Purpose: Keep you and others safe.
    How it helps: Hemianopia commonly makes driving unsafe; rehab may assess candidacy.

11. Head-of-bed elevation (≈30°) & sleep positioning.
    Description: Sleep with the head raised.
    Purpose: Help symptoms from high intracranial pressure (ICP) like morning headache or transient visual blur.
    How it helps: Gravity lowers venous congestion and can ease ICP-related symptoms (supportive only).

12. Hydration and bowel regimen support.
    Description: Fluids, fiber, stool softeners if needed.
    Purpose: Counter constipation from inactivity, opioids, and anti-nausea drugs.
    How it helps: Reduces straining and discomfort that can worsen headaches.

13. Mindfulness, counseling, & coping skills.
    Description: Psych-oncology support, meditation apps, CBT for health anxiety.
    Purpose: Lower stress, which worsens symptom perception.
    How it helps: Improves quality of life and adherence to rehab.

14. Fatigue management & energy conservation.
    Description: Pacing, scheduled rests, activity planning.
    Purpose: Fight cancer-related and steroid-related fatigue.
    How it helps: Keeps vision tasks for your best energy windows.

15. Balance & vestibular therapy if gait is unsteady.
    Description: PT exercises to improve balance and gait.
    Purpose: Reduce falls.
    How it helps: Addresses brain pathway disruption affecting balance.

16. Lid taping, moisture chambers, frequent lubricant use at night (if facial nerve weakness or incomplete eyelid closure).
    Purpose: Protect the cornea from drying and scratches.
    How it helps: Prevents exposure keratopathy and vision-threatening ulcers.

17. Photophobia (light-sensitivity) management.
    Description: Tinted lenses (rose or gray), hats, dimmer apps.
    Purpose: Reduce discomfort and headache.
    How it helps: Filters intense light without overly darkening indoors.

18. Seizure safety planning.
    Description: Avoid heights/unsupervised swimming; bathroom door unlocked; family training.
    Purpose: Prevent injury if a seizure occurs.
    How it helps: Reduces trauma and fear while antiepileptics are optimized.

19. Palliative care early involvement.
    Description: Specialist team to tackle symptoms and planning.
    Purpose: Maximize comfort and functioning from the beginning.
    How it helps: Better symptom control, decision support, and caregiver coaching.

20. Clinical trial navigation.
    Description: Help finding trials for GBM that may improve overall control (which indirectly helps vision by limiting tumor growth).
    Purpose: Access promising therapies (e.g., TTFields, immunotherapy combinations).
    How it helps: Tumor control is the strongest “vision protection.” JAMA NetworkPMC

---

Drug treatments

(class • typical dose/timing • purpose • how it works • common cautions)

1. Temozolomide (alkylating chemotherapy).
   Dose/time: With radiation, 75 mg/m² daily for ~6 weeks; then maintenance 150–200 mg/m² daily on days 1–5 every 28 days for 6 cycles (adjust per labs).
   Purpose: Standard drug with radiotherapy to control GBM.
   How it works: Damages tumor DNA; tumors with MGMT-methylation respond better.
   Cautions: Nausea, low blood counts; discuss PJP (Pneumocystis) prophylaxis during the chemo-radiation phase per local protocol. PMCNew England Journal of MedicineeviQ

2. Dexamethasone (corticosteroid).
   Dose/time: Use the lowest effective dose; common practice is 4 mg every 6 hours initially for severe symptoms, then taper quickly; after surgery many guidelines cap routine doses at or below 16 mg/day and step down as soon as possible.
   Purpose: Shrink vasogenic edema to relieve headache, nausea, and visual blur from raised ICP.
   How it works: Leaks less fluid from capillaries around tumor.
   Cautions: High sugar, insomnia, infection risk, muscle weakness, mood changes; taper to avoid withdrawal. PMC+1Alberta Health Services

3. Bevacizumab (anti-VEGF monoclonal antibody).
   Dose/time: Often 10 mg/kg IV every 2 weeks (or 15 mg/kg q3w) in recurrence or for steroid-refractory edema/radiation necrosis—guided by oncology.
   Purpose: Reduce edema and steroid needs; can ease vision symptoms linked to swelling.
   How it works: Blocks VEGF to decrease leaky tumor vessels.
   Cautions: Hypertension, bleeding, clots, wound-healing issues; generally does not extend overall survival in GBM but improves symptoms/radiographic edema. PMC

4. Levetiracetam (antiepileptic).
   Dose/time: Common start 500 mg twice daily, titrate to 1000–3000 mg/day.
   Purpose: Prevent or control seizures (which can cause transient vision loss or “visual auras”).
   How it works: Modulates synaptic vesicle protein (SV2A).
   Cautions: Somnolence, mood changes; interactions are fewer than with enzyme-inducing AEDs. PMC

5. Hyperosmolar therapy for acute ICP spikes – 3% hypertonic saline or mannitol (hospital setting).
   Dose/time: Protocol-based boluses (e.g., 3% NaCl or 23.4% NaCl; mannitol 0.25–1 g/kg IV).
   Purpose: Rapidly lower dangerous intracranial pressure that threatens vision and life.
   How it works: Osmotic gradient pulls fluid out of brain tissue.
   Cautions: Needs ICU-level monitoring (sodium, osmolality, kidney status). PMC

6. Acetazolamide (carbonic anhydrase inhibitor).
   Dose/time: Often 250–500 mg twice daily, titrate; off-label in tumor-related ICP when papilledema is prominent and surgery/radiation are pending; first-line in idiopathic intracranial hypertension.
   Purpose: Lower cerebrospinal fluid production to ease papilledema-related blur.
   How it works: Blocks CSF secretion; mild diuretic effect.
   Cautions: Tingling, kidney stones; avoid if sulfa-allergic; evidence strongest in IIH, not GBM—use is individualized. JNNP

7. Lomustine/CCNU (nitrosourea) – common at recurrence; sometimes combined with TMZ in MGMT-methylated disease.
   Dose/time: 110 mg/m² orally every 6 weeks (dose-adjust per counts).
   Purpose: Disease control at recurrence; occasionally part of combination strategies.
   How it works: Alkylates DNA.
   Cautions: Delayed marrow suppression, fatigue, rare lung toxicity with high cumulative doses. PMC

8. Ondansetron (anti-nausea).
   Dose/time: 8 mg before chemotherapy, then per antiemetic plan.
   Purpose: Prevent chemo-related nausea so you can eat and stay hydrated.
   How it works: 5-HT3 receptor blockade.
   Cautions: Constipation, QT prolongation with higher doses. NCCN

9. Artificial tears / ocular lubricants (carboxymethylcellulose, polyvinyl alcohol).
   Dose/time: 4–6×/day and at bedtime (gel/ointment).
   Purpose: Protect the surface of the eye when blink is weak or exposure is present.
   How it works: Keeps cornea moist to prevent erosions and infection.
   Cautions: Minimal; preservative-free preferred for frequent use.

10. PJP prophylaxis (e.g., trimethoprim-sulfamethoxazole) during the TMZ-with-radiation phase if your center recommends it.
    Dose/time: One double-strength tablet 3 times weekly or daily low-dose (per protocol).
    Purpose: Prevent Pneumocystis pneumonia when immunity dips with chemo-radiation and/or steroids.
    How it works: Blocks folate pathways in the organism.
    Cautions: Allergy, low counts, sun sensitivity; practice varies by center, but many guidelines still recommend it during concurrent TMZ-RT. eviQSpringerLink

Note: The single most effective “vision treatment” is overall tumor control—maximal safe surgery plus radiotherapy with temozolomide, and in appropriate cases Tumor Treating Fields (TTFields) with maintenance TMZ. These are core standards that support everything else we do for vision. New England Journal of MedicineJAMA Network

---

Dietary “molecular” supplements

(typical consumer doses • what they do • important cautions)

Supplements don’t treat GBM and can interact with cancer care. Talk to your oncology team before starting any of these—especially during radiation or chemotherapy—because some antioxidants may blunt treatment effects or interact with drugs. Cancer.govAmerican Cancer Society

1. Vitamin D3 (if deficient): 1000–2000 IU/day.
   Function/mechanism: Supports bone/immune health; deficiency is common during illness.
   Caution: Monitor levels; avoid excess.

2. Omega-3 (EPA/DHA): 1–2 g/day combined EPA+DHA.
   Function: Anti-inflammatory; may help appetite and triglycerides.
   Caution: Bleeding risk at high doses; pause before surgery if advised.

3. Magnesium (citrate or glycinate): 200–400 mg/night.
   Function: Helps muscle cramps, sleep, constipation.
   Caution: Loose stools with higher doses. UVM Health

4. Melatonin: 3–10 mg at bedtime.
   Function: Sleep support; studied as adjunct in oncology; may ease steroid-induced insomnia.
   Caution: Morning drowsiness in some.

5. Ginger extract: 500–1000 mg/day (or fresh ginger).
   Function: Nausea support.
   Caution: Bleeding risk at very high doses; interacts with some anticoagulants.

6. Probiotic (lactobacillus/bifidobacterium mix): per label.
   Function: Gut regularity during chemo-induced bowel changes.
   Caution: Avoid if severely immunosuppressed—ask your team.

7. Curcumin (turmeric extract, with piperine): 500–1000 mg/day.
   Function: Anti-inflammatory pathways (NF-κB).
   Caution: Interactions possible; mixed data during RT—ask your oncologist. Cancer.govOxford Academic

8. Green tea extract (EGCG): 200–400 mg/day.
   Function: Antioxidant/anti-inflammatory; may help fatigue focus.
   Caution: Can interact with certain drugs and liver metabolism—clear it with the team. Veterans Affairs

9. Selenium: 100–200 mcg/day.
   Function: Antioxidant enzyme support (glutathione peroxidase).
   Caution: Narrow therapeutic window; do not exceed label.

10. CoQ10: 100–200 mg/day with food.
    Function: Mitochondrial energy support; may help fatigue.
    Caution: Interactions with warfarin; discuss first.

Bottom line on supplements: Food first. Use supplements only to fix a true deficiency or a specific side effect, and always clear them with your oncology pharmacist/doctor. Cancer.gov

---

Advanced” immune or regenerative approaches

These are research/clinical-trial therapies, not routine care. Ask about trial eligibility at a high-volume neuro-oncology center.

1. Nivolumab (PD-1 inhibitor, immunotherapy).
   Dose in trials: 240 mg IV q2 weeks or 480 mg q4 weeks.
   Function: Unleashes T-cells against tumor.
   Evidence: In the CheckMate-143 phase 3 trial for recurrent GBM, nivolumab did not improve overall survival compared with bevacizumab; combinations are still being studied.
   Key side effects: Immune-related inflammation (thyroid, lungs, colon, skin). PMC

2. Pembrolizumab (PD-1 inhibitor).
   Dose in trials: 200 mg IV q3 weeks or 400 mg q6 weeks.
   Function: Similar to nivolumab; ongoing trials in combinations (e.g., with oncolytic viruses).
   Evidence: Mixed; combinations like DNX-2401 + pembrolizumab show signals but remain experimental. Nature

3. Dendritic cell vaccine (e.g., DCVax-L).
   What it is: A personalized vaccine made from your tumor and your immune cells.
   Evidence: A large externally controlled phase 3 analysis suggests overall survival benefit when added to standard care; methodology has been debated, but interest is high. Side effects generally mild. JAMA Network+1

4. Oncolytic virus therapy (e.g., DNX-2401).
   What it is: Modified virus injected into tumor to kill cancer cells and spark immunity.
   Evidence: Early-phase trials show safety and occasional durable responses; combinations with PD-1 blockade under study. PubMed

5. CAR-T or TIL therapies (research).
   What it is: Re-engineered immune cells (T-cells) targeting markers like EGFRvIII.
   Evidence: Early studies only; risks include brain swelling (edema) and neurotoxicity—available mainly in trials.

6. Tumor Treating Fields (TTFields) – not a drug, but a device to mention here.
   What it is: Wearable arrays deliver low-intensity alternating electric fields to disrupt tumor cell division; used with maintenance temozolomide in newly diagnosed GBM.
   Evidence: EF-14 randomized trial showed improved progression-free and overall survival with TTFields + TMZ versus TMZ alone. Side effects mainly scalp irritation. JAMA Network

---

Surgeries

1. Maximal safe resection (craniotomy; sometimes awake mapping).
   Why: Remove as much tumor as safely possible to improve survival and reduce pressure; mapping protects speech/motor/visual tracts. This often gives the best chance to reduce vision-threatening swelling. PMC

2. Stereotactic biopsy (needle biopsy).
   Why: When the tumor is in a risky spot, a small tissue sample secures the diagnosis and molecular markers to guide therapy.

3. Laser interstitial thermal therapy (LITT).
   Why: For deep/eloquent tumors or recurrences that are hard to resect; a probe heats and destroys tumor under MRI guidance, often with short hospital stay. PubMedMDPI

4. Ventricular CSF diversion (VP shunt or endoscopic third ventriculostomy).
   Why: If tumor blocks CSF flow causing hydrocephalus and papilledema; diverting fluid lowers pressure and protects vision.

5. Protective eyelid procedures (temporary tarsorrhaphy) when eyelids won’t close.
   Why: In facial nerve weakness or severe exposure, partially sewing the lids together protects the cornea from ulcers and permanent vision loss.

---

Prevention tips

1. Get early neuro-ophthalmology evaluation at diagnosis and after surgery/radiation—small changes can be caught and treated sooner.

2. Keep steroid dose as low and brief as possible; ask about taper plans at every visit. Alberta Health Services

3. Follow seizure-safety guidance even if you’ve had only one event. PMC

4. Protect dry or exposed eyes (lubricants, taping at night).

5. Optimize blood sugar, blood pressure, and sleep—these worsen headaches and vision strain.

6. Use vision rehab early—waiting risks accidents and entrenched habits. Lippincott Journals

7. Avoid unvetted supplements during chemo-radiation; clear every product with oncology. Cancer.gov

8. Keep vaccines current (per oncology advice) to reduce infections while on steroids/chemo.

9. Plan the home environment for safety (lighting, contrast, clutter-free walkways).

10. Ask regularly about clinical trials—overall tumor control protects vision best. PMC

---

When to see a doctor urgently

• Sudden vision loss, new blind spot, or a “black curtain.”

• New or worsening double vision, drooping eyelid, or unequal pupils.

• Severe/new headache, morning vomiting, or brief vision dimming when standing (ICP spikes).

• Any seizure, or a change in seizure pattern.

• New weakness, speech trouble, confusion, or clumsiness.
  If these happen, go to the emergency department.

---

Simple diet tips: what to eat—and what to avoid

1. Eat: protein with every meal (eggs, fish, legumes) to maintain strength.
   Avoid: skipping meals—worsens fatigue and dizziness.

2. Eat: whole grains, fruits, and fiber for regular bowels.
   Avoid: very low-fiber diets that worsen constipation from anti-nausea meds.

3. Eat: potassium-rich produce (bananas, leafy greens) unless restricted.
   Avoid: excess salt, especially on higher-dose steroids (swelling, blood pressure).

4. Drink: steady fluids all day.
   Avoid: dehydration—worsens headaches and fatigue.

5. Eat: healthy fats (olive oil, nuts) and omega-3s (fish) a few times weekly.
   Avoid: very greasy meals if nausea is an issue.

6. Choose: small, frequent meals when appetite is low.
   Avoid: large heavy meals that trigger nausea.

7. Include: calcium + vitamin D foods to protect bones on steroids.
   Avoid: grapefruit and Seville orange products if your pharmacist says they interact with your meds.

8. Use: ginger tea/crackers for queasiness.
   Avoid: strong odors/spices if they trigger nausea.

9. Ask before using: any supplement—especially high-dose antioxidants during radiation/chemo.
   Avoid: St. John’s wort, high-dose green tea extract, or other herbs that can alter drug levels. Cancer.govVeterans Affairs

10. Plan: with an oncology dietitian if weight swings up/down.
    Avoid: crash diets; nutrition supports treatment tolerance. Cancer.goV

Frequently asked questions (FAQ)

1) Can GBM cause permanent blindness?
Yes, if it directly damages the optic nerves or occipital cortex, or if uncontrolled pressure injures the optic nerves. Early treatment aims to prevent this. PubMed

2) Will my vision get better after treatment?
Sometimes. Vision may improve when swelling falls after surgery, steroids, bevacizumab, or radiotherapy. Vision rehab improves function even if the visual field doesn’t fully return. Lippincott Journals

3) Are prisms a cure for hemianopia?
No. Prisms don’t regrow brain tissue, but they can shift images to help you notice things on the blind side and can ease some kinds of double vision. American Academy of Ophthalmology

4) Is it safe to drive with a hemianopia?
Usually not. Many countries restrict driving after this kind of field loss. Ask your doctor and consider a driving rehab evaluation.

5) How long should I stay on dexamethasone?
Only as long as needed for symptom control, then taper as fast as is safe. Long courses bring side effects. Alberta Health Services

6) Do anti-VEGF drugs like bevacizumab help me live longer?
They often improve symptoms and MRI swelling and can reduce steroid needs, but they have not clearly extended overall survival in GBM. PMC

7) Which seizure medicine is preferred in brain-tumor patients?
Levetiracetam is commonly preferred because it’s effective and has fewer drug interactions, though choices are individualized. PMC

8) Are immunotherapy drugs a breakthrough for GBM?
So far, single-agent PD-1 inhibitors haven’t beaten standard options in recurrent GBM; trials are testing combinations and vaccines. PMC

9) What is TTFields and does it help?
A wearable device that delivers low-intensity electric fields to disrupt tumor cell division; added to maintenance temozolomide, it improved survival in a large randomized trial. JAMA Network

10) Can diet or supplements treat GBM?
No. Use nutrition to support strength and manage treatment side effects. Always clear supplements with oncology to avoid interactions. Cancer.gov

11) Why do I see worse in the morning?
Overnight, ICP can be higher; sitting up and taking prescribed meds often helps while definitive tumor care proceeds.

12) My eyelid won’t close—what now?
Protect the eye with frequent lubricants, moisture shields, and taping at night; severe cases may need a temporary eyelid procedure.

13) Can radiation harm the optic nerves?
High doses can cause radiation optic neuropathy months later; modern planning aims to keep doses below safety thresholds, but risk is never zero. (Your team uses contouring guidelines to protect the visual apparatus.) The Green Journal

14) What if vision suddenly drops while I’m on treatment?
Treat it as an emergency—tumor progression, bleeding, or pressure spikes need rapid evaluation.

15) How can I keep track of changes?
Use simple home checks: cover each eye in turn weekly; scan a grid or calendar; note any new missing areas or double vision and report promptly.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: August 14, 2025.